Putting It All Together: IWV May Be Valued at $403
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Should l Buy CELC?
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares Russell 3000 ETF (IWV) has an implied analyst target price of $403.11, indicating an 11.64% upside from its recent trading price of $361.08.
Notable Holdings with Upside: Key underlying holdings in IWV include PACS Group Inc, Inspired Entertainment Inc, and Celcuity Inc, all showing significant potential upside based on analyst targets.
Price Comparisons: PACS is currently priced at $11.73 with a target of $32.00 (172.80% upside), INSE at $8.49 with a target of $13.67 (60.97% upside), and CELC at $50.38 with a target of $69.43 (37.81% upside).
Investor Considerations: Analysts' target prices may reflect optimism but could also lead to downgrades if they are not aligned with current market conditions, prompting further investor research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 102.010
Low
94.00
Averages
106.50
High
126.00
Current: 102.010
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Reports Q4 Non-GAAP EPS Beat Expectations
- Earnings Highlights: Celcuity reported a Q4 Non-GAAP EPS of -$0.73, beating market expectations by $0.28, indicating potential improvement in the company's financial performance.
- Rising Operating Expenses: Total operating expenses for Q4 reached $49.2 million, a 35% increase from $36.4 million in Q4 2024, reflecting ongoing investments in R&D and marketing.
- Strong Cash Reserves: At the end of fiscal year 2025, Celcuity had $441.5 million in cash, cash equivalents, and short-term investments, expected to finance operations through 2027, enhancing financial stability.
- FDA Priority Review: Celcuity received FDA priority review for its breast cancer therapy, marking a strategic advancement in the biotech sector that could accelerate product launch and enhance market competitiveness.
See More
Celcuity Reports $177 Million Net Loss for 2025 Amid Regulatory Progress
- Poor Financial Performance: Celcuity reported a net loss of $177 million for 2025, translating to a loss of $3.79 per share, indicating significant challenges in profitability despite holding $441.5 million in cash and short-term investments, which is expected to sustain operations through 2027.
- Increased R&D Expenses: Research and development expenses surged to $145 million in 2025, an increase of $40.8 million from the previous year, primarily driven by rising employee and consulting costs, which will exert ongoing pressure on the company's financial health and future investment capabilities.
- Significant Clinical Progress: In 2025, Celcuity achieved FDA acceptance of its new drug application for gedatolisib with priority review, and the VICTORIA-1 trial demonstrated unprecedented efficacy data, potentially setting new benchmarks for HR-positive HER2-negative advanced breast cancer treatment, thereby enhancing market competitiveness.
- Market Readiness Initiatives: The company has made substantial strides in preparing for the commercial launch of gedatolisib, including building a robust sales force and engaging with key healthcare decision-makers, which will help secure a favorable position in the future market, despite challenges in ensuring patient adherence to IV administration.
See More
Celcuity Q4 2025 Earnings Call Highlights
- FDA Priority Review: Celcuity's new drug application for gedatolisib has received FDA priority review, with a PDUFA goal date of July 17, 2026, which could open up a market opportunity exceeding $5 billion, with projected peak annual revenues of $2.5 billion, significantly enhancing the company's market position.
- Clinical Trial Data: In the VIKTORIA-1 clinical trial, the gedatolisib triplet therapy demonstrated a median progression-free survival of 9.3 months, far surpassing fulvestrant's 2 months, indicating its potential as a new standard of care in HR-positive/HER2-negative advanced breast cancer treatment.
- Financial Performance: The net loss for Q4 2025 was $51 million, or $0.97 per share, an increase from $36.7 million in the same quarter of 2024, reflecting high investments in commercialization preparations, with cash reserves expected to sustain operations through 2027.
- Market Readiness: Management has largely completed the establishment of the sales force and internal systems, actively advancing the commercialization of gedatolisib, and aims to enhance engagement with physicians and patients through proactive market strategies and supportive clinical data to increase market share.
See More
MillerKnoll Earnings Decline Sparks 14% Drop
- MillerKnoll Earnings Report: MillerKnoll reported fiscal third-quarter adjusted earnings of 43 cents per share on revenue of $926.6 million, showing a 6% year-over-year revenue increase but a 2% decline in earnings, indicating pressure on profitability.
- Middle East Conflict Impact: The company warned of an expected $8 million to $9 million impact in the fourth quarter due to the Middle East conflict, stemming from reduced shipments to the region and increased logistics costs, which may further affect future performance.
- Karman Performance: Karman posted fiscal fourth-quarter adjusted earnings of 11 cents per share, falling short of the 12 cents expected by analysts, yet its revenue of $134.5 million exceeded the $132.6 million consensus, demonstrating resilience in the aerospace and defense sector.
- Worthington Steel Decline: Worthington Steel's adjusted earnings for the third quarter fell to 27 cents per share from 35 cents a year ago, leading to a 14% drop in share price, reflecting the profitability pressures and challenges faced in the steel industry.
See More
Deerfield Management Company Increases Stake in Celcuity
- Share Increase: Deerfield Management Company disclosed in its SEC filing on February 17, 2026, that it purchased an additional 980,470 shares of Celcuity in the fourth quarter, with an estimated trade value of $80.60 million, indicating strong confidence in the company.
- Value Growth: By quarter-end, Deerfield's total position in Celcuity reached $170.95 million, up $134.72 million from the previous quarter, reflecting the combined impact of new purchases and share price appreciation.
- Outstanding Market Performance: Celcuity's stock price surged over 1,040% in the past year, significantly outperforming the S&P 500's approximately 19% gain, showcasing its robust growth potential in the biotechnology sector.
- FDA Priority Review: Celcuity's lead drug candidate, Gedatolisib, has received FDA priority review, with a decision expected on July 17, 2026, which could further drive the company's stock price up and attract more investor interest.
See More
Deerfield Management Increases Celcuity Stake by 980,470 Shares
- Stake Increase: Deerfield Management Company increased its stake in Celcuity by 980,470 shares in Q4, with an estimated trade value of $80.60 million, reflecting confidence in the biotech company's market potential.
- Position Value Growth: By quarter-end, Deerfield's total position in Celcuity reached $170.95 million, up $134.72 million from the previous quarter, indicating a significant impact from both trading activity and stock price appreciation.
- FDA Priority Review: Celcuity's new drug application for gedatolisib has received FDA priority review for hormone receptor-positive, HER2-negative advanced breast cancer, with a decision date set for July 17, 2026, potentially opening significant market opportunities for the company.
- Positive Market Reaction: Celcuity's shares have skyrocketed over 1,000% in the past year, demonstrating strong investor interest in its precision oncology platform and therapeutic pipeline, with the upcoming quarterly report likely to further influence market sentiment.
See More
Celcuity Reports Q4 Non-GAAP EPS Beat Expectations
- Earnings Highlights: Celcuity reported a Q4 Non-GAAP EPS of -$0.73, beating market expectations by $0.28, indicating potential improvement in the company's financial performance.
- Rising Operating Expenses: Total operating expenses for Q4 reached $49.2 million, a 35% increase from $36.4 million in Q4 2024, reflecting ongoing investments in R&D and marketing.
- Strong Cash Reserves: At the end of fiscal year 2025, Celcuity had $441.5 million in cash, cash equivalents, and short-term investments, expected to finance operations through 2027, enhancing financial stability.
- FDA Priority Review: Celcuity received FDA priority review for its breast cancer therapy, marking a strategic advancement in the biotech sector that could accelerate product launch and enhance market competitiveness.
See More
Celcuity Reports $177 Million Net Loss for 2025 Amid Regulatory Progress
- Poor Financial Performance: Celcuity reported a net loss of $177 million for 2025, translating to a loss of $3.79 per share, indicating significant challenges in profitability despite holding $441.5 million in cash and short-term investments, which is expected to sustain operations through 2027.
- Increased R&D Expenses: Research and development expenses surged to $145 million in 2025, an increase of $40.8 million from the previous year, primarily driven by rising employee and consulting costs, which will exert ongoing pressure on the company's financial health and future investment capabilities.
- Significant Clinical Progress: In 2025, Celcuity achieved FDA acceptance of its new drug application for gedatolisib with priority review, and the VICTORIA-1 trial demonstrated unprecedented efficacy data, potentially setting new benchmarks for HR-positive HER2-negative advanced breast cancer treatment, thereby enhancing market competitiveness.
- Market Readiness Initiatives: The company has made substantial strides in preparing for the commercial launch of gedatolisib, including building a robust sales force and engaging with key healthcare decision-makers, which will help secure a favorable position in the future market, despite challenges in ensuring patient adherence to IV administration.
See More
Celcuity Q4 2025 Earnings Call Highlights
- FDA Priority Review: Celcuity's new drug application for gedatolisib has received FDA priority review, with a PDUFA goal date of July 17, 2026, which could open up a market opportunity exceeding $5 billion, with projected peak annual revenues of $2.5 billion, significantly enhancing the company's market position.
- Clinical Trial Data: In the VIKTORIA-1 clinical trial, the gedatolisib triplet therapy demonstrated a median progression-free survival of 9.3 months, far surpassing fulvestrant's 2 months, indicating its potential as a new standard of care in HR-positive/HER2-negative advanced breast cancer treatment.
- Financial Performance: The net loss for Q4 2025 was $51 million, or $0.97 per share, an increase from $36.7 million in the same quarter of 2024, reflecting high investments in commercialization preparations, with cash reserves expected to sustain operations through 2027.
- Market Readiness: Management has largely completed the establishment of the sales force and internal systems, actively advancing the commercialization of gedatolisib, and aims to enhance engagement with physicians and patients through proactive market strategies and supportive clinical data to increase market share.
See More
MillerKnoll Earnings Decline Sparks 14% Drop
- MillerKnoll Earnings Report: MillerKnoll reported fiscal third-quarter adjusted earnings of 43 cents per share on revenue of $926.6 million, showing a 6% year-over-year revenue increase but a 2% decline in earnings, indicating pressure on profitability.
- Middle East Conflict Impact: The company warned of an expected $8 million to $9 million impact in the fourth quarter due to the Middle East conflict, stemming from reduced shipments to the region and increased logistics costs, which may further affect future performance.
- Karman Performance: Karman posted fiscal fourth-quarter adjusted earnings of 11 cents per share, falling short of the 12 cents expected by analysts, yet its revenue of $134.5 million exceeded the $132.6 million consensus, demonstrating resilience in the aerospace and defense sector.
- Worthington Steel Decline: Worthington Steel's adjusted earnings for the third quarter fell to 27 cents per share from 35 cents a year ago, leading to a 14% drop in share price, reflecting the profitability pressures and challenges faced in the steel industry.
See More
Deerfield Management Company Increases Stake in Celcuity
- Share Increase: Deerfield Management Company disclosed in its SEC filing on February 17, 2026, that it purchased an additional 980,470 shares of Celcuity in the fourth quarter, with an estimated trade value of $80.60 million, indicating strong confidence in the company.
- Value Growth: By quarter-end, Deerfield's total position in Celcuity reached $170.95 million, up $134.72 million from the previous quarter, reflecting the combined impact of new purchases and share price appreciation.
- Outstanding Market Performance: Celcuity's stock price surged over 1,040% in the past year, significantly outperforming the S&P 500's approximately 19% gain, showcasing its robust growth potential in the biotechnology sector.
- FDA Priority Review: Celcuity's lead drug candidate, Gedatolisib, has received FDA priority review, with a decision expected on July 17, 2026, which could further drive the company's stock price up and attract more investor interest.
See More
Deerfield Management Increases Celcuity Stake by 980,470 Shares
- Stake Increase: Deerfield Management Company increased its stake in Celcuity by 980,470 shares in Q4, with an estimated trade value of $80.60 million, reflecting confidence in the biotech company's market potential.
- Position Value Growth: By quarter-end, Deerfield's total position in Celcuity reached $170.95 million, up $134.72 million from the previous quarter, indicating a significant impact from both trading activity and stock price appreciation.
- FDA Priority Review: Celcuity's new drug application for gedatolisib has received FDA priority review for hormone receptor-positive, HER2-negative advanced breast cancer, with a decision date set for July 17, 2026, potentially opening significant market opportunities for the company.
- Positive Market Reaction: Celcuity's shares have skyrocketed over 1,000% in the past year, demonstrating strong investor interest in its precision oncology platform and therapeutic pipeline, with the upcoming quarterly report likely to further influence market sentiment.
See More
